Overview

A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001)

Status:
Active, not recruiting
Trial end date:
2023-04-14
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to identify the maximum tolerated dose (MTD) of belzutifan Tablets and/or the recommended Phase 2 dose (RP2D) of belzutifan Tablets in patients with advanced solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Peloton Therapeutics, Inc.